Twinbeech Capital LP Madrigal Pharmaceuticals, Inc. Transaction History
Twinbeech Capital LP
- $4.99 Billion
- Q3 2024
A detailed history of Twinbeech Capital LP transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Twinbeech Capital LP holds 6,428 shares of MDGL stock, worth $2.17 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
6,428Holding current value
$2.17 Million% of portfolio
0.03%Shares
6 transactions
Others Institutions Holding MDGL
# of Institutions
294Shares Held
21.9MCall Options Held
819KPut Options Held
644K-
Janus Henderson Group PLC London, X02.48MShares$838 Million0.28% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$691 Million29.57% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$686 Million6.48% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$674 Million6.74% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$668 Million4.49% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.79B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...